ImClone May Face More House Hearings
- Share via
PHARMACEUTICALS
*
ImClone Systems Inc. may be the subject of additional hearings by the House Energy and Commerce Committee, Chairman W. J. “Billy” Tauzin (R-La.) said.
The committee is examining ImClone’s handling of its Erbitux cancer-drug application, which the Food and Drug Administration rejected in December. The rejection triggered an 86% drop in shares and a probe into whether the company misled investors.
Further probes will focus on what went wrong with Erbitux, and ways to improve the FDA’s review process, Tauzin said.
Shares of New York-based ImClone rose 20 cents to $8.20 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
